InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

InflaRx N.V.NASDAQ: IFRX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -€165.31K, compared with €0 a year earlier. Trailing-twelve-month accounts receivables was €1.95M.

Context

  • Accounts receivables amounted to 7212.1% of revenue in FY2025, up 7212.1 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -€165.31K or moves back toward the trailing-twelve-month quarterly average of €487.52K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€165.31K-107.8% QoQ
Last fiscal yearDec 2025
€2.12M— YoY
LTMMar 2026
€1.95M+3826.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
2.12M EUR
Year-over-year change
—

Accounts Receivables vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3826.6% is the highest of 6, against a peer median of -26.6%.
  • Accounts receivables amounts to 6648.5% of revenue for IFRX, versus a peer median of 135.0%.
IFRX Competitors
Accounts Receivables for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€1.95M EUR+3826.6%—6648.5%
STROSutro Biopharma, Inc.LTM Mar 2026$1.08M USD-93.9%-4.6%1.1%
CNTBConnect Biopharma Holdings LimitedFY2025$776K USD+198.4%+512.8%1212.5%
ATYRaTyr Pharma, Inc.LTM Mar 2026$511K USD-26.6%—268.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$183K USD-87.7%——
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
IMAImageneBio IncLTM Mar 2026$0 USD+100.0%——
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding IFRX) —-26.6%+254.1%135.0%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(43.83M)
Depreciation & Amortization669.43K596.6K567.78K485.11K402.93K
Deferred Income Tax1.16M0000
Stock-Based Compensation4.33M6.04M3.41M4.07M0
Change in Working Capital1.54M(9.77M)1M(2.28M)4.66M
Accounts Receivables00002.12M
Inventory00(11.37M)4.47M6.63M
Accounts Payables316.11K(3.52M)00(5.76M)
Other Working Capital1.22M(6.25M)12.37M(6.75M)1.68M
Other Non-Cash Items(2M)(1.13M)(131.29K)(4.76M)4.84M
Operating Cash Flow(39.94M)(33.74M)(37.81M)(48.56M)(33.92M)
Capital Expenditures(37.78K)(162.39K)(81.1K)(46.87K)(111.13K)
Acquisitions (Net)37.78K(19.52M)000
Purchases of Investments(97.52M)(64.47M)(104.05M)(35.34M)(44.28M)
Sales of Investments71.6M84M86.44M87.75M47.5M
Other Investing Activities(37.78K)19.52M01(3)
Investing Cash Flow(25.95M)19.36M(17.7M)52.36M3.11M
Debt Repayment(360.64K)(364.43K)(373.98K)(388.11K)(357.58K)
Common Stock Issued65.14M2.35M56.48M1.1M32.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.2M)(47.74K)(3.12M)(323.73K)14.11K
Financing Cash Flow61.58M1.94M52.99M386.45K32M
Effect of Forex Changes4.59M2.46M(974.1K)1.41M(1.37M)
Net Change in Cash281.31K(9.98M)(3.5M)5.61M(179.66K)
Free Cash Flow(39.97M)(33.91M)(37.89M)(48.6M)(34.03M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.